Powder: -20°C for 3 years | In solvent: -80°C for 1 year
FK 3311 (COX-2 Inhibitor V) 是一种细胞渗透性和口服磺胺类药物,可作为 COX-2 抑制剂和非甾体抗炎药。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 235 | 现货 | ||
2 mg | ¥ 333 | 现货 | ||
5 mg | ¥ 541 | 现货 | ||
10 mg | ¥ 866 | 现货 | ||
25 mg | ¥ 1,480 | 现货 | ||
50 mg | ¥ 2,280 | 现货 | ||
100 mg | ¥ 3,380 | 现货 | ||
200 mg | ¥ 4,850 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 729 | 现货 |
产品描述 | FK 3311 (COX-2 Inhibitor V) is a cell permeable and orally available sulfonanilide that acts as a COX-2 inhibitor and non-steroidal anti-inflammatory drug (NSAID) |
体内活性 | Survival rate was significantly better (p <0.05) and serum GOT levels 30 min after reperfusion were significantly lower (p <0.05) in the FK 3311(FK) high-dose group compared to the other two groups. Four hours after reperfusion, GPT levels and liver tissue flow were significantly (p <0.05) better in the FK high-dose group compared to the control. Both 30 min and 4 hr after reperfusion, serum TxB(2) levels were significantly lower in the FK high-dose group compared to the control (p <0.05)[1]. |
动物实验 | Inbred male Lewis rats weighing 200-260 g were used. The donor liver was perfused with cold University of Wisconsin (UW) solution and then stored in the same solution at 4 degrees C for 18 hr. After the preservation period, orthotopic liver transplantation was performed. Animals were divided into three groups: the control group; the FK low-dose group (1 mg/kg FK3311 i.v. 20 min before reperfusion); and the FK high-dose group (3 mg/kg FK3311. 20 min before reperfusion). Survival rate, serum GOT and GPT levels, liver tissue blood flow, and serum thromboxane B(2) (TxB(2)) levels were compared among groups[1]. |
别名 | N-[4-乙酰基-2-(2,4-二氟苯氧基)苯基]-甲烷磺酰胺, FK-3311, COX-2 Inhibitor V |
分子量 | 341.33 |
分子式 | C15H13F2NO4S |
CAS No. | 116686-15-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (292.97 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9297 mL | 14.6486 mL | 29.2972 mL | 73.2429 mL |
5 mM | 0.5859 mL | 2.9297 mL | 5.8594 mL | 14.6486 mL | |
10 mM | 0.293 mL | 1.4649 mL | 2.9297 mL | 7.3243 mL | |
20 mM | 0.1465 mL | 0.7324 mL | 1.4649 mL | 3.6621 mL | |
50 mM | 0.0586 mL | 0.293 mL | 0.5859 mL | 1.4649 mL | |
100 mM | 0.0293 mL | 0.1465 mL | 0.293 mL | 0.7324 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
FK 3311 116686-15-8 Immunology/Inflammation Neuroscience COX Cyclooxygenase FK3311 Inhibitor inhibit N-[4-乙酰基-2-(2,4-二氟苯氧基)苯基]-甲烷磺酰胺 FK-3311 COX-2 Inhibitor V inhibitor